Increased detection of latent tuberculosis by tuberculin skin test and booster phenomenon in early rheumatoid arthritis patients

Rheumatology International

Volumn 35, Issue 9, 2015, Pages 1555-1559

  Perez Barbosa L ^a   Esquivel Valerio, J A ^a   Arana Guajardo, A C ^a   Vega Morales, D ^a   Riega Torres, J ^a   Garza Elizondo, M A ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Booster immunization; Diagnostic test; Latent tuberculosis; Rheumatoid arthritis; Tuberculin skin test

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PREDNISONE; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CELLULAR IMMUNITY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; INCIDENCE; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TUBERCULIN TEST; AGED; COMPARATIVE STUDY; COMPLICATION; EARLY DIAGNOSIS; MIDDLE AGED;

ADULT; AGED; ARTHRITIS, RHEUMATOID; EARLY DIAGNOSIS; FEMALE; HUMANS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; TUBERCULIN TEST;

EID: 84939463543     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-015-3246-9     Document Type: Article

References (32)

1. Carmona L, Hernández-García C, Vadillo C, Pato E, Balsa A, González-Alvaro I et al (2003) Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30:1436–1439
2. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122–2127
3. Carmona L, Gómez-Reino JJ, Rodíguez-Velarde V, Montero D, Pascual-Gómez E, Mola EM et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766–1772
4. Migita K, Umeno T, Miyagawa K, Izumi Y, Sasaki E, Kakugawa T et al (2012) on the other hand it is necessary to identify patients who do not require prophylaxis to prevent adverse events of anti-TB drugs. Rheumatol Int 32:1375–1377
5. Haroon M, Martin U, Devlin J (2012) High incidence of intolerance to tuberculosis chemoprophylaxis. Rheumatol Int 32:33–37
6. Cagatay T, Kilicaslan Z, Catagay P, Mertsoylu M, Gulbaran Z, Yildiz R et al (2011) TNF-alpha antagonist therapy modify the tuberculin skin test response. Rheumatol Int 31:1147–1151
7. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al (2012) Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:625–639
8. Acevedo-Vásquez E, Ponce de León D, Gamboa-Cárdenas R (2009) Latent infection and tuberculosis disease in rheumatoid arthritis patients. Rheum Dis Clin North Am 35:163–181
9. Paimela L, Johansson-Stephansson EA, Koskimies S, Leirisalo-Repo M (1990) Depressed cutaneous cell-mediated immunity in early rheumatoid arthritis. Clin Exp Rheumatol 8:433–437
10. Coaccioli S, Di Cato L, Marioli D, Patucchi E, Pizzuti C, Ponteggia M et al (2000) Impaired cutaneous cell-mediated immunity in newly diagnosed rheumatoid arthritis. Panminerva Med 42:263–266
11. Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, Cucho M, Alfaro J, Perich R et al (2005) Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 64:1360–1361
12. Arana-Guajardo A, Pérez-Barbosa L, Vega-Morales D, Riega-Torres J, Esquivel- Valerio J, Garza-Elizondo M (2014) Application of a prediction model for the progression of rheumatoid arthritis in patients with undifferentiated arthritis. Reumatol Clin. doi:10.1016/j.reuma.2014.01.007
13. Arnett F, Edworthy S, Bloch D, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
14. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588
15. Banal F, Dougados M, Combescure C, Gossec L (2009) Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: a systematic literature review and meta-analysis. Ann Rheum Dis 68:1184–1191
16. WHO-Global tuberculosis database – 2014. http://www.who.int/tb/publications/global_report/en/. Accessed February 23, 2015
17. Abud-Mendoza C, Martínez-Martínez MU, Macías-Mendoza JDJ, Magaña-Aquino M (2010) Should tuberculin skin test be positive to give latent tuberculosis treatment before tumor necrosis factor-alpha inhibitors in selected patients in developing countries? J Rheumatol 37:672–673
18. Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D et al (2009) QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 33:586–593
19. Agarwal S, Das SK, Agarwal GC, Srivastava R (2014) Steroids decrease prevalence of positive tuberculin skin test in rheumatoid arthritis: implications on anti-TNF therapies. Interdiscip Perspect Infect Dis. doi:10.1155/2014/430134
20. Tamborenea MN, Tate G, Mysler E, Debonis J, Schijedman A (2010) Prevalence of positive ppd in a cohort of rheumatoid arthritis patients. Rheumatol Int 30:613–616
21. Kraut A, Coodin M, Plessis R, McLean D (2004) Predictors of positive tuberculin skin test (TST) results after 2-step TST among health care workers in Manitoba, Canada. Clin Infect Dis 39:e113–e114
22. Cengiz K, Seker A (2006) Boosted tuberculin skin testing in hemodialysis patients. Am J Infect Control 34:383–387
23. Teixeira EG, Kristski A, Ruffino-Netto A, Steffen R, Lapa E, Silva JR, Belo M et al (2008) Two-step tuberculin skin test and booster phenomenon prevalence among Brazilian medical students. Int J Tuberc Lung Dis 12:1407–1413
24. Ostrosky-Zeichner L, Rangel-Frausto MS, García-Romero E, Vázquez A, Ibarra MJ, Ponce de León-Rosales S (2000) Tuberculosis in health personnel: importance of surveillance and control programs. Salud Publica Mex 42:48–52
25. Haynes BF, Markert ML, Sempowski GD, Patel DD, Hale LP (2000) The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Ann Rev Immunol 18:529–560
26. Weyand CM, Fulbright JW, Goronzy JJ (2003) Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp Gerontol 38:833–841
27. Lee KH, Jung SY, Ha YJ, Lee SK, Park YB (2012) Tuberculin reaction is not attenuated in patients with rheumatoid arthritis living in a region with intermediate burden of tuberculosis. Rheumatol Int 32:1421–1424
28. Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Lagana B, Gatta L et al (2014) Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med 8:1–8. doi:10.3109/07853890.2014.941919
29. Catagay T, Aydin M, Sunmez S, Catagay P, Gulbaran Z, Gul A et al (2010) Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol Int 30:1459–1463
30. Mrozek N, Pereira B, Soubrier M, Gourdon F, Laurichesse H (2012) Screening of tuberculosis before biologics. Med Mal Infect 42:1–4
31. Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149:177–184
32. Hanta I, Ozbek S, Kuleci S, Seydaoglu G, Ozytilmaz E (2012) Detection of latent tuberculosis infection in rheumatologic diseases before anti-TNFα therapy: tuberculin skin test versus IFN-γ assay. Rheumatol Int 32:3599–35603